

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
14 July 2022 (14.07.2022)



(10) International Publication Number
WO 2022/150621 A1

(51) International Patent Classification:
A61K 31/4418 (2006.01) *A61P 7/06* (2006.01)

Published:
— with international search report (Art. 21(3))

(21) International Application Number:
PCT/US2022/011666

(22) International Filing Date:
07 January 2022 (07.01.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/135,327 08 January 2021 (08.01.2021) US
63/135,316 08 January 2021 (08.01.2021) US
63/177,104 20 April 2021 (20.04.2021) US
63/177,098 20 April 2021 (20.04.2021) US

(71) Applicant: **AKEBIA THERAPEUTICS, INC.** [US/US];
245 First Street, Suite 1400, Cambridge, MA 02142 (US).

(72) Inventors: **BURKE, Steven**; c/o Akebia Therapeutics,
Inc., 245 First Street, Suite 1400, Cambridge, MA 02142
(US). **CHAVAN, Ajit**; c/o Akebia Therapeutics, Inc., 245
First Street, Suite 1400, Cambridge, MA 02142 (US).
KHAWAJA, Zeeshan; c/o Akebia Therapeutics, Inc., 245
First Street, Suite 1400, Cambridge, MA 02142 (US).

(74) Agent: **ESPINO, Christine G.** et al.; Proskauer Rose LLP,
One International Place, Boston, MA 02110 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: THERAPEUTIC METHODS USING VADADUSTAT

(57) Abstract: This invention provides methods for the treatment of anemia in patients with chronic kidney disease (CKD) using vadadustat (Compound 1). Methods described herein provide alternative dosing regimens for patients having anemia. In addition, methods herein are suitable for patients converting from a previous anemia treatment including erythropoietin stimulating agent (ESA), patients who are on dialysis (e.g., peritoneal dialysis or hemodialysis), or CKD patients having certain hemoglobin (Hb) levels.

WO 2022/150621 A1